FORMULATION AND IN VITRO EVALUTION OF MATRIX TABLET CONTAINING SILDENAFIL CITRATE
*Ashish bhandari1, Seema Gosain2, Ganesh Kumar Bhatt1, Preeti Kothiyal1
1Shri Guru Ram Rai Institute of Technology & Science P.O. Box - 80, Patel Nagar, Dehradun 248001, Uttarakhand , India.
2Dehradun institute of technology, Mussourie-Diversion Road, Makkawala, Dehradun, Uttarakhand-248009, India.
ABSTRACT
Sildenafil citrate is a selective inhibitor of phosphodiesterase type 5
enzyme (PDE5), it offers potential to treat patients with pulmonary
hypertension by selectively inhibiting phosphodiesterase type five
pathways in the lung. It is recommended for selected patients with
pulmonary arterial hypertension, and has favourable effects on
endothelial function. Controlled release matrix tablets of Sildenafil
citrate is designed by simplex lattice design and evaluating the
relationship and influence of different content levels of HPMC
(Hypromellose), Eudragit L100 and Carbopol (Carbomer), in order to
achieve a zero-order release of Sildenafil citrate. Tablets were
prepared by wet granulation process and evaluated for different pre
and post compression parameter, from these matrix tablets drug
release was prolonged, leading to achieve an effective therapy with
low dosage of the drug, to reduce the frequency of medication.
Keywords: Sildenafil citrate, Pulmonary hypertension, Matrix tablet, HPMC, Eudragit, controlled release.
[Download Article]
[Download Certifiate]